A young man in his late 30s with a history of pulmonary tuberculosis presented with complaints of hoarseness of voice persisting for 6 months. Chest auscultation revealed diminished breath sounds over ...
Yashoda Hospitals in Hyderabad saves 20-year-old's life with innovative Pulmonary Thrombectomy device, preventing long-term ...
Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition ...
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial ...
Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...
An independent data monitoring committee has recommended terminating the ZENITH study early based on the results.
Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.
XOMA Royalty Corp. (XOMA), a biotechnology royalty aggregator, Monday announced that it now owns royalty and milestone interest in ...
Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...
Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...
Significantly higher levels of the miRNA molecule miR-3591-5p were seen in those with CHD and moderate to severe PAH than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback